Welcome to SynAct Pharma AB’s website. We use cookies to optimise your use of our website. A cookie is a text file that is stored on your computer. If you want further information about what a cookie is, what cookies we use, what the purpose of the cookie is or how you can block or delete cookies, please read “About cookies“. By continuing, you agree to our use of cookies.

Close

logo

print
  • About us
    About us
      • The company in brief
      • New partnership
      • History
      • Board of Directors
      • Management
  • Research & development
    Research & development
      • Resolution Therapy
      • Melanocortin derived therapy - Pharmacology
      • Melanocortin derived therapy - Applied in the clinic
      • Pipeline overview
      • The AP1189 development program
      • Rheumatoid Arthritis
      • Nephrotic Syndrome
      • Covid-19
      • Ongoing clinical studies
      • Scientific council
  • Corporate governance
    Corporate governance
      • Corporate governance
      • General meetings
      • Board of Directors
      • Management
      • Auditors
      • Articles of association
  • Investors
    Investors
      • The share
        • Ownership
      • Annual reports
      • Interim reports
      • Prospectuses
      • Press releases
      • Presentations
      • Synact in media
      • Calendar
      • Subscribe
      • Investor relations contact
      • Financial advisor
  • Media
    Media
      • Press releases
      • News
      • Synact in media
      • Subscribe
      • Image Bank
      • Media contact
  • Contact
    Contact
      • Office
      • Investors & media
      • Financial advisor
About us
  • The company in brief
  • New partnership
  • History
  • Board of Directors
  • Management
Research & development
  • Resolution Therapy
  • Melanocortin derived therapy – Pharmacology
  • Melanocortin derived therapy – Applied in the clinic
  • Pipeline overview
  • The AP1189 development program
  • Rheumatoid Arthritis
  • Nephrotic Syndrome
  • Covid-19
  • Ongoing clinical studies
  • Scientific council
Corporate governance
  • Corporate governance
  • General meetings
  • Board of Directors
  • Management
  • Auditors
  • Articles of association
Investors
  • The share
    • Ownership
  • Annual reports
  • Interim reports
  • Prospectuses
  • Press releases
  • Presentations
  • Synact in media
  • Calendar
  • Subscribe
  • Investor relations contact
  • Financial advisor
Media
  • Press releases
  • News
  • Synact in media
  • Subscribe
  • Image Bank
  • Media contact
Contact
  • Office
  • Investors & media
  • Financial advisor

SynAct PharmaSynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

  • January 11, 2021Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB
  • January 11, 2021Flaggningsmeddelande i SynAct Pharma AB
  • November 13, 2020Pressmeddelande, 13 november 2020 SynAct Pharma publicerar delårsrapport Q3 2020
  • November 9, 2020SynAct Pharma tillkännager positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit
All press releases

News

  • April 2, 2020BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)
  • April 1, 2020Synact Pharma in spotlightanalysen (in Swedish)
  • October 28, 2019Redeye: Adding an indication
All news

Donation to Reumatikerförbundet

Read more

Calendar

  • February 12, 2021Bokslutskommuniké, 2020
All events
The ShareXSAT (SYNACT): Loading..

Subscribe to our press releases

Language


Information type

About us
  • The company in brief
  • New partnership
  • History
  • Board of Directors
  • Management
Research & development
  • Resolution Therapy
  • Melanocortin derived therapy – Pharmacology
  • Melanocortin derived therapy – Applied in the clinic
  • Pipeline overview
  • The AP1189 development program
  • Rheumatoid Arthritis
  • Nephrotic Syndrome
  • Covid-19
  • Ongoing clinical studies
  • Scientific council
Corporate governance
  • Corporate governance
  • General meetings
  • Board of Directors
  • Management
  • Auditors
  • Articles of association
Investors
  • The share
  • Annual reports
  • Interim reports
  • Prospectuses
  • Press releases
  • Presentations
  • Synact in media
  • Calendar
  • Subscribe
  • Investor relations contact
  • Financial advisor
Media
  • Press releases
  • News
  • Synact in media
  • Subscribe
  • Image Bank
  • Media contact
Contact
  • Office
  • Investors & media
  • Financial advisor

SynAct Pharma AB, c/o Medicon Village AB, Scheelevägen 2,SE-223 81 Lund, Sweden.

Telephone +45 28 44 75 67. E-post joo@synactpharma.com. Company registration number: 559058-4826.

  • About personal data
  • About Cookies